Terms: = Leukemia AND KMT2C, ENSG00000055609, MLL3, 58508
90 results:
1. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.
Yu K; Deuitch N; Merguerian M; Cunningham L; Davis J; Bresciani E; Diemer J; Andrews E; Young A; Donovan F; Sood R; Craft K; Chong S; Chandrasekharappa S; Mullikin J; Liu PP
Blood Adv; 2024 Jan; 8(2):497-511. PubMed ID: 38019014
[TBL] [Abstract] [Full Text] [Related]
2. The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China.
Yang J; Zhao L; Wu Y; Niu T; Gong Y; Chen X; Huang X; Liu J; Dai Y; Ma H
Cancer Med; 2023 Dec; 12(23):21111-21117. PubMed ID: 37937729
[TBL] [Abstract] [Full Text] [Related]
3. mll3 regulates the
Zhu C; Soto-Feliciano YM; Morris JP; Huang CH; Koche RP; Ho YJ; Banito A; Chen CW; Shroff A; Tian S; Livshits G; Chen CC; Fennell M; Armstrong SA; Allis CD; Tschaharganeh DF; Lowe SW
Elife; 2023 Jun; 12():. PubMed ID: 37261974
[TBL] [Abstract] [Full Text] [Related]
4. KMT2D Deficiency Promotes Myeloid leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition.
Xu J; Zhong A; Zhang S; Chen M; Zhang L; Hang X; Zheng J; Wu B; Deng X; Pan X; Wang Z; Qi L; Shi K; Li S; Wang Y; Wang M; Chen X; Zhang Q; Liu P; Gale RP; Chen C; Liu Y; Niu T
Adv Sci (Weinh); 2023 Jul; 10(19):e2206098. PubMed ID: 37142882
[TBL] [Abstract] [Full Text] [Related]
5. Clustered PHD domains in KMT2/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers.
Stroynowska-Czerwinska AM; Klimczak M; Pastor M; Kazrani AA; Misztal K; Bochtler M
Cell Mol Life Sci; 2023 Jan; 80(1):23. PubMed ID: 36598580
[TBL] [Abstract] [Full Text] [Related]
6. KMT2A-D pathogenicity, prevalence, and variation according to a population database.
Larson JK; Hunter-Schlichting DN; Crowgey EL; Mills LJ; Druley TE; Marcotte EL
Cancer Med; 2023 Mar; 12(6):7234-7245. PubMed ID: 36479909
[TBL] [Abstract] [Full Text] [Related]
7. Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity.
Ning H; Huang S; Lei Y; Zhi R; Yan H; Jin J; Hu Z; Guo K; Liu J; Yang J; Liu Z; Ba Y; Gao X; Hu D
Nat Commun; 2022 Nov; 13(1):6578. PubMed ID: 36323669
[TBL] [Abstract] [Full Text] [Related]
8. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract] [Full Text] [Related]
9. Advances in the Treatment of Hairy Cell leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract] [Full Text] [Related]
10. Exploration of the Activation Mechanism of the Epigenetic Regulator mll3: A QM/MM Study.
Miranda-Rojas S; Blanco-Esperguez K; Tuñón I; Kästner J; Mendizábal F
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356675
[TBL] [Abstract] [Full Text] [Related]
11. PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome.
Ohkawa T; Nishimura A; Kosaki K; Aoki-Nogami Y; Tomizawa D; Kashimada K; Morio T; Kato M; Mizutani S; Takagi M
J Hum Genet; 2022 Jan; 67(1):51-54. PubMed ID: 34341476
[TBL] [Abstract] [Full Text] [Related]
12. Loss of kmt2c reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification.
Maurya S; Yang W; Tamai M; Zhang Q; Erdmann-Gilmore P; Bystry A; Martins Rodrigues F; Valentine MC; Wong WH; Townsend R; Druley TE
Epigenetics; 2022; 17(2):220-238. PubMed ID: 34304711
[TBL] [Abstract] [Full Text] [Related]
13. MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model.
Pereira-Martins DA; Weinhäuser I; Coelho-Silva JL; França-Neto PL; Almeida LY; Bianco TM; Silva CL; França RF; Traina F; Rego EM; Schuringa JJ; Lucena-Araujo AR
Cell Death Dis; 2021 Apr; 12(4):371. PubMed ID: 33824267
[TBL] [Abstract] [Full Text] [Related]
14. kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Chen R; Okeyo-Owuor T; Patel RM; Casey EB; Cluster AS; Yang W; Magee JA
Cell Rep; 2021 Feb; 34(7):108751. PubMed ID: 33596429
[TBL] [Abstract] [Full Text] [Related]
15. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
[TBL] [Abstract] [Full Text] [Related]
16. mll3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Wu HT; Liu YE; Hsu KW; Wang YF; Chan YC; Chen Y; Chen DR
Am J Chin Med; 2020; 48(5):1221-1241. PubMed ID: 32668964
[TBL] [Abstract] [Full Text] [Related]
17. M2 macrophage-derived extracellular vesicles promote gastric cancer progression via a microRNA-130b-3p/mll3/GRHL2 signaling cascade.
Zhang Y; Meng W; Yue P; Li X
J Exp Clin Cancer Res; 2020 Jul; 39(1):134. PubMed ID: 32660626
[TBL] [Abstract] [Full Text] [Related]
18. H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes.
Kwon M; Park K; Hyun K; Lee JH; Zhou L; Cho YW; Ge K; Skalnik DG; Muir TW; Kim J
Nucleic Acids Res; 2020 Jun; 48(10):5442-5456. PubMed ID: 32365172
[TBL] [Abstract] [Full Text] [Related]
19. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
[TBL] [Abstract] [Full Text] [Related]
20. Cancer-derived UTX TPR mutations G137V and D336G impair interaction with mll3/4 complexes and affect UTX subcellular localization.
Kato H; Asamitsu K; Sun W; Kitajima S; Yoshizawa-Sugata N; Okamoto T; Masai H; Poellinger L
Oncogene; 2020 Apr; 39(16):3322-3335. PubMed ID: 32071397
[TBL] [Abstract] [Full Text] [Related]
[Next]
